Mark P. Christiansen, MD
Medical Director, Endocrinologist, Principal Investigator
- Phone: 925-930-7267
- Email: mchristiansen@diabloclinical.com
Experience:
2021-Present Medical Director, Investigator, Diablo Clinical Research
2009-2020 Co-Medical Director, Investigator, Diablo Clinical Research
2007-2009 Investigator, Diablo Clinical Research
2002-2009 Endocrinologist, Valley Medical Center
1994-2002 Assistant Clinical Physician, San Francisco General Hospital
1990-1994 Contra Costa Endocrine Associates
Drug and Device Phase I-IV Studies:
PI for 300+ studies/Sub-I for 350+ studies:
Diabetes Device: Continuous Glucose Monitor, Glucometer/Blood Glucose Meter, Insulin Pump, Artificial Pancreas/Hybrid Closed Loop
Endocrine/Cardiovascular/Weight Loss: Diabetes Mellitus Types 1 and 2, Diabetic Peripheral Neuropathy, Hypercholesterolemia, Hypertension, Metabolic Syndrome, Obesity/Weight Loss, Dyslipidemia, Osteoporosis, Osteopenia,
GI: Celiac Disease, GERD, IBS, Lactose Intolerance
Healthy Volunteer: Phase 1 Studies, Device studies (indications include diabetes, cardiovascular), Marketing/Usability Studies, Bioequivalence, Cosmetic Skin Studies, Nutrition Studies
Pain/Neuroscience: Diabetic Peripheral Neuropathy, Migraine, Osteoarthritis, Chronic Low Back Pain, Fibromyalgia, Gout, Carpal Tunnel Syndrome
Vaccine: RSV, COVID-19, Flu, Shingles, CMV, HPV, Pneumococcal, eColi
Women’s/Men’s Health: Hot Flash/Menopausal Symptoms, Female Sexual Dysfunction, Overactive Bladder, Erectile Dysfunction, Premature Ejaculation, Sarcopenia
Education:
1988-1990 Fellowship, Diabetes, Endocrinology and Metabolism, University of California, San Francisco
1985-1988 Internship and Residency, Internal Medicine, University Hospitals Cleveland Medical Center
1985 Doctor of Medicine, Case Western Reserve University
1982-1983 Pathology Fellowship, University Hospitals Cleveland Medical Center
1980 Stanford University, BS, Biological Sciences
Licensure:
Medical License State of California #G62892
National Board of Medical Examiners, 1989
American Board of Internal Medicine, 1988
American Board of Diabetes, Endocrinology, and Metabolism, 1991-2001
Certified Clinical Densitometrist, 2004
Training:
Good Clinical Practice
Standard Operating Procedures for Diablo Clinical Research
Protecting Human Research Participants
C-SSRS Certified Since 2011
Memberships/Awards/Appointments:
Alpha Omega Alpha, Case Western Reserve University, 1985
Max Miller Award in Medicine, Case Western Reserve University, 1985
Publications:
Abstracts
Christiansen, MP, P. Linfoot, S. Turner, and M. Hellerstein. 1995. Energy Restriction and NIDDM: Effects upon hepatic glucose output, Diabetes 45 A.
Christiansen, MP, P. Linfoot, R. Neese, S. Turner, and M. Hellerstein. 1996. Effects of energy restriction on lipolysis, free fatty acid fluxes, gluconeogenesis, and glycogenolysis in NIDDM. Diabetes. 45: 321A.
Christiansen, MP, P. Linfoot, R. Neese, and M. Hellerstein. 1997. Metformin: Effects upon postabsorptive intrahepatic carbohydrate fluxes. Diabetes. 46: 244A.
Hellerstein, M., R. Neese, P. Linfoot, M. Christiansen, and S. Turner. 1995. Contribution from gluconeogenesis to fasting blood glucose measured by mass isotopomer distribution analysis in normal humans. Diabetes. 45.
Hellerstein, M., R. Neese, P. Linfoot, M. Christiansen, and A. Letscher. 1996. Detailed characterization in fasting humans of intrahepatic fluxes through gluconeogenesis and glycogen. Diabetes. 45:36A.
Christiansen, M.P., B. Hoh, C. Ho, A. Strawford. 2001. Effects of insulin upon endogenous glucose production in HIV seropositive individuals with lipodystrophy on highly active antiretroviral therapy. Diabetes. 50:suppl 2 A 512.
Christiansen, MP. 2015. Performance of a fourth-generation glucose sensor with two different real-time display devices in adults. Advanced Technologies & Treatments for Diabetes. ATTD-0389
Christiansen, MP, Green, C., Pardo, S., Warchal-Windham, ME, Harrison, B., Morin, R., Bailey, T. October 2015. Accuracy and user performance evaluation of a new blood glucose monitoring system in development for use with Contour Next test strips. Presented at the 15th Annual Meeting of the Diabetes Technology Society (DTS), Bethesda, Maryland
Bailey, T., Wallace, J., Pardo, S., Warchal-Windham, ME, Harrison, B.,
Morin, R., Christiansen, MP. October 2015. Accuracy and user performance evaluation of a new blood glucose monitoring system in development for use with Contour Plus Test Strips. Presented at the 15th Annual Meeting of the Diabetes Technology Society (DTS), Bethesda, Maryland
Articles
Christiansen MP, Klaff LJ, Bailey TS, Brazg R, Carlson G, Tweden KS. 2019.
A Prospective Multicenter Evaluation of the Accuracy and Safety of an Implanted Continuous Glucose Sensor: The PRECISION Study. Diabetes Technol Ther. 21(5):231-237.
Christiansen MP, Klaff LJ, Brazg R, Chang AR, Levy CJ, Lam D, Denham DS, Atiee G, Bode BW, Walters SJ, Kelley L, Bailey TS. 2018. A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. Diabetes Technol Ther. 20(3):197-206.
Christiansen MP, Garg SK, Brazg R, Bode BW, Bailey TS, Slover RH, Sullivan A, Huang S, Shin J, Lee SW, Kaufman FR. 2017. Accuracy of a Fourth-Generation Subcutaneous Continuous Glucose Sensor. Diabetes Technol Ther. 19(8):446-456.
Mark Christiansen, MD, Timothy Bailey, MD, Elaine Watkins, DO, David Liljenquist, MD, David Price, MD, Katherine Nakamura, PhD, Robert Boock, PhD, and Thomas Peyser, PhD. 2013. A New-Generation Continuous Glucose Monitoring System: Improved Accuracy and Reliability Compared with a Previous-Generation System. DTT. 15: 881-888
Don, B., A. Sebastian, M. Cheitlin, M. Christiansen, and M. Schambelan. 1990. Pseudohyperkalemia Caused by Fist Clenching During Phlebotomy. N. Engl J Med. 322: 1290-1292.
Hellerstein, M., M. Christiansen, S. Kaempfer, and C. Kletke. 1991. Measurement of de novo Hepatic Lipogenesis in Humans Using Stable Isotopes. J Clin Invest. 87: 1841-1852.
Kaempfer, S., M. Blackham, M. Christiansen, K. Wu, and M. Hellerstein. 1991. Fraction of Hepatic Cytosolic Acetyl-CoA Derived from Glucose in vivo: Relation to PDH Phosphorylation State. Am J Physiology. 260:E865-875.
Hellerstein, M., C. Grunfeld, K. Wu, M. Christiansen. 1993. Increased de novo Hepatic Lipogenesis in Human Immunodeficiency Infection. J Clin Endocrinol Metab. 76: 559-565.
Hellerstein, M., R. Neese, P. Linfoot, M. Christiansen, S. Turner, and A. Letscher. 1997. Hepatic Gluconeogenic Fluxes and Glycogen Turnover During Fasting in Humans: A Stable Isotope Study. J Clin Invest. 100: 1305-19.
Siler, S.Q., R.A. Neese, M.P. Christiansen, and M.K. Hellerstein. 1998. The Inhibition of Gluconeogenesis Following Alcohol in Humans. Am J Physiol. 275: E897-907.
Christiansen, M., M. Hellerstein. 1998. Effects of Metformin on Hepatic Glucose Metabolism. Curr Opin Endo Diab. 5:252-255.
Strawford, A., T. Barbieri, R. Neese, M. Van Loan, M. Christiansen, R. Hoh, G. Sathayan, R. Skowronski, J. King, and M. Hellerstein. 1999. Effects of Nandrolone Deconoate Therapy in Borderline Hypogonadal Men with HIV-Associated Weight Loss. Journal of Acquired Immune Deficiency and Human Retrovirology. 20: 137-146.
Parks, E., R.M. Krauss, M. P. Christiansen, R. Neese, and M. Hellerstein. 1999. Effects of a Low-fat Diet on Sources of Fatty Acids for VLDL Triglyceride Production. J Clin Invest. 104:1087-1096.
Strawford, A., T. Barbieri, M. Van Loan, E. Parks, D. Catlin, N. Barton, R. Neese, M. Christiansen, J. King, and M. Hellerstein. 1999. Effects of Resistance Exercise Combined with Supraphysiologic Androgen Therapy Including an Anabolic Steroid, Oxandrolone, on Lean Tissue Accrual and Muscle Strength in Eugonadal Men with HIV-Related Weight Loss. JAMA 281: 1282-1290.
Davis, A., M. Christiansen, S. Klein, M. Hellerstein, R. Ostlund. 2000. Effects of d-chiro-inositol on Glucose Metabolism in Insulin Resistant Subjects. Diabetes Care. 23: 1000-1005.
Wang, W., A. Bassinger, R. Neese, M. Christiansen, M. Hellerstein. 2000. Effects of Nicotinic Acid on Free Fatty Acid Kinetics and Pathways of Glucose Metabolism in Humans. Am J Physiol Endocrinol Metab. 279:E50-59.
Christiansen, M., P. Linfoot, R. Neese, M. Hellerstein. 2000. Effects of Caloric Restriction Upon Endogenous Glucose Production and Substrate Utilization in DM2. Diabetes. 49: 1691-1699.
Wang, W, A. Basinger, B.Shane, S. Myong., M. Christiansen, M. Hellerstein. 2001. Effect of Nicotinic Acid Administration on Hepatic Very Low Density Lipoprotein-Triglyceride Production. Am J Physiol Endocrinol Metab. 280:E540-547.
Bailey T, Bode BW, Christiansen MP, Klaff LJ, Alva S. 2015. The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System. Diabetes Technol Ther. 17(11):787-94.
Vedala A, Wang W, Neese RA, Christiansen MP, Hellerstein MK. 2006. Delayed Secretory Pathway Contributions to VLDL-Triglycerides from Plasma NEFA, Diet, and de novo Lipogenesis in Humans. J Lipid Res. 47(11):2562-74.
Swarbrick MM, Stanhope KL, Elliott SS, Graham JL, Krauss RM, Christiansen MP, Griffen SC, Keim NL, Havel PJ. 2008. Consumption of Fructose-Sweetened Beverages for 10 Weeks Increases Postprandial Triacylglycerol and Apolipoprotein-B Concentrations in Overweight and Obese Women. Br J Nutr. 100(5):947-52.
Hoss U, Budiman ES, Liu H, Christiansen MP. 2013. Continuous Glucose Monitoring in the Subcutaneous Tissue Over a 14-day Sensor Wear Period.
J Diabetes Sci Technol. 7(5):1210-9.
Hoss U, Budiman ES, Liu H, Christiansen MP. 2014. Feasibility of Factory Calibration for Subcutaneous Glucose Sensors in Subjects with Diabetes. 2014. J Diabetes Sci Technol. 8(1):89-94.
Bailey TS, Alva S, Bode BW, Christiansen MP, Klaff LJ. 2016. Response to the Comment on "The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System" by Bailey et al. Diabetes Technol Ther. 18(5):336-7.
Buckingham BA, Christiansen MP, Forlenza GP, Wadwa RP, Peyser TA, Lee JB, O'Connor J, Dassau E, Huyett LM, Layne JE, Ly TT. 2018. Performance of the Omnipod Personalized Model Predictive Control Algorithm with Meal Bolus Challenges in Adults with Type 1 Diabetes. Diabetes Technol Ther. 20(9):585-595.
Slover RH, Tryggestad JB, DiMeglio LA, Fox LA, Bode BW, Bailey TS, Brazg R, Christiansen MP, Sherr JL, Tsalikian E, Kaiserman KB, Sullivan A, Huang S, Shin J, Lee SW, Kaufman FR. 2018. Accuracy of a Fourth-Generation Continuous Glucose Monitoring System in Children and Adolescents with Type 1 Diabetes. Diabetes Technol Ther. 20(9):576-584.
Buckingham BA, Forlenza GP, Pinsker JE, Christiansen MP, Wadwa RP, Schneider J, Peyser TA, Dassau E, Lee JB, O'Connor J, Layne JE, Ly TT. 2018. Safety and Feasibility of the OmniPod Hybrid Closed-Loop System in Adult, Adolescent, and Pediatric Patients with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm. Diabetes Technol Ther. 20(4):257-262.
Forlenza GP, Buckingham BA, Christiansen MP, Wadwa RP, Peyser TA, Lee JB, O'Connor J, Dassau E, Huyett LM, Layne JE, Ly TT. 2019. Performance of Omnipod Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise in Adults with Type 1 Diabetes. Diabetes Technol Ther. 21(5):265-272.
Adler, Stuart P., Nicole Lewis, Anthony Conlon, Mark P. Christiansen, Mohamed Al-lbrahim, Richard Rupp, Tong-Ming Fu, Oliver Bautista, Huaping Tang, Dai Wang, Alison Fisher, Timothy Culp, Rituparna Das, Karen Beck, Gretchen Tamms, and Luwy Musey; and the V160-001 Study Group. 2019. Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects. The Journal of Infectious Diseases. 2019;220:411-9
